These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2836527)

  • 1. CA 50 serum levels in patients with liver diseases.
    Genolla J; Moragas G; Mañe S; Rosell M; Cuartero A; Encabo G; Ruibal A
    Int J Biol Markers; 1987; 2(3):207-8. PubMed ID: 2836527
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevation of CA 125 in patients with benign and malignant ascites.
    Bergmann JF; Bidart JM; George M; Beaugrand M; Levy VG; Bohuon C
    Cancer; 1987 Jan; 59(2):213-7. PubMed ID: 3026603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
    Collazos J
    Cancer; 1992 Sep; 70(5):1202-3. PubMed ID: 1381271
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
    Fabris C; Basso DA; Leandro G; Meggiato T; Elba S; Panozzo MP; Del Favero G; Fogar P; Di Mario F; Naccarato R
    Cancer; 1991 Oct; 68(8):1795-8. PubMed ID: 1717126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood coagulation and fibrinolysis in Ugandan patients with cirrhosis and hepatocellular carcinoma.
    Alpidovsky VK; Vogel CL; Sadikali F; Primack A
    East Afr Med J; 1974 May; 51(5):396-408. PubMed ID: 4367587
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum globulin subfraction variations in liver cirrhosis and hepatoma.
    Kageyama T; Kimoto S; Toda H; Oyabu H; Watanabe I
    Bull Osaka Med Sch; 1975 Oct; 21(2):132-9. PubMed ID: 181107
    [No Abstract]   [Full Text] [Related]  

  • 7. [A clinical study of serum erythropoietin concentrations in patients with liver cirrhosis and hepatocellular carcinomas].
    Takezaki E; Murakami S; Kagawa K; Omori H; Nishibayashi H
    Gan No Rinsho; 1990 Jan; 36(1):19-22. PubMed ID: 2153846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum concentrations of tissue polypeptide antigen and alpha 1-fetoprotein in patients with primary liver cancer, liver metastasis and liver cirrhosis].
    Polterauer P; Legenstein E; Müller M
    Wien Klin Wochenschr; 1985 Apr; 97(9):417-20. PubMed ID: 2408389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumoral markers in liver cirrhosis and hepatocellular carcinoma].
    Gómez Rubio M; de Cuenca Morón B; Domínguez M
    Gastroenterol Hepatol; 2005 May; 28(5):308. PubMed ID: 15871818
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum calcitonin levels in hepatocellular carcinoma and other liver diseases.
    Fujiyama S; Sagara K; Sato T
    Horm Metab Res; 1986 Jun; 18(6):421-2. PubMed ID: 3015758
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum selenium concentration in patients with liver cirrhosis and hepatocellular carcinoma.
    Buljevac M; Romić Z; Vucelić B; Banić M; Krznarić Z; Plesko S
    Acta Med Croatica; 1996; 50(1):11-4. PubMed ID: 8776109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heterogeneity of alpha-fetoprotein with concanavalin A-binding properties in the serum and ascites of liver neoplasms and liver cirrhosis].
    Fujise K; Nagamori S; Hasumura S; Homma S; Sujino H; Kameda H
    Nihon Shokakibyo Gakkai Zasshi; 1983 Nov; 80(11):2363-8. PubMed ID: 6200631
    [No Abstract]   [Full Text] [Related]  

  • 13. Presence of a hepatoma-liver antigen in the sera of patients with primary hepatocellular carcinoma.
    Oon CJ; Yo Sui Lan
    Singapore Med J; 1979 Jun; 20(2):317-22. PubMed ID: 92056
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein.
    Iacovazzi PA; Trisolini A; Barletta D; Elba S; Manghisi OG; Correale M
    Clin Chem Lab Med; 2001 Oct; 39(10):961-5. PubMed ID: 11758611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of CA 125 as a serum marker of hepatocellular carcinoma.
    Elias J; Kew MC
    Int J Cancer; 1990 Nov; 46(5):805-7. PubMed ID: 2172170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.
    Finkelmeier F; Canli Ö; Peiffer KH; Walter D; Tal A; Koch C; Pession U; Vermehren J; Trojan J; Zeuzem S; Piiper A; Greten FR; Grammatikos G; Waidmann O
    PLoS One; 2018; 13(7):e0200855. PubMed ID: 30011326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum sialic acid levels in liver cirrhosis and liver cancer (author's transl)].
    Matsuzaki S; Itakura M; Iwamura K; Kamiguchi H
    Nihon Shokakibyo Gakkai Zasshi; 1981 Dec; 78(12):2395-401. PubMed ID: 6281495
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rheumatoid factor in liver cirrhosis and hepatoma (author's transl)].
    Caballero Vallés PJ; Miramón García MA; Roldán Rincón AC; Ruiz Pérez de Villar MJ
    Med Clin (Barc); 1982 Feb; 78(3):84-7. PubMed ID: 6281590
    [No Abstract]   [Full Text] [Related]  

  • 19. Carbohydrate antigen 19-9 as a serum marker of hepatocellular carcinoma: comparison with alpha-foetoprotein.
    Kew MC; Berger EL; Koprowski H
    Br J Cancer; 1987 Jul; 56(1):86-8. PubMed ID: 2441732
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnostic value of serum copper, zinc and plasma fibrinogen in cirrhotic patients with and without hepatocellular carcinoma.
    Doğan UB; Cindoruk M; Dumlu S; Unlü R; Unal S
    Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):476-7. PubMed ID: 9494860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.